Yahoo · Oct 30, 2026
SGIOY vs. UTHR: Which Stock Is the Better Value Option?
SGIOY vs. UTHR: Which Stock Is the Better Value Option?
SG
OTC · SGIOY
Shionogi & Co., Ltd.
Healthcare · Drug Manufacturers - Specialty & Generic
$9.57
Up+$0.06 (+0.63%)
Updated Nov 5, 2026, 4:15 AM
SID Score
6.3/10
Composite research score
Smart Money
46/100
Neutral
- Market cap
- 14.53B
- P/E ratio
- 13.35
- Dividend yield
- 2.10%
- 52-week range
- — – —
- Volume
- 6.86K
- Avg. volume
- 100.96K
Price performance · SGIOY
SGIOY price history
1M range · 0 trading sessions · Daily adjusted prices
SGIOY does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest SGIOY news
The latest Smart Investors Daily articles mentioning SGIOY.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SGIOY research
Overview
Company profile and research snapshot.
Company profile
SHIONOGI & CO UNSP/ADR
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
Yahoo · Oct 29, 2026
Shionogi & Co., Ltd. Unsponsored ADR (SGIOY) Q2 Earnings Lag Estimates
Shionogi & Co. (SGIOY) delivered earnings and revenue surprises of -38.46% and +5.14%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Yahoo · Oct 25, 2026
How Investors Are Reacting To Shionogi (TSE:4507) Clinical Trial Results
Shionogi reported a series of positive IDWeek 2026 updates, including Phase 3 data for XOCOVA in COVID-19 post-exposure prophylaxis, new U.S. and global evidence for Fetroja in resistant Gram-negative infections, and non-inferiority Phase 3 results for oral olorofim in invasive aspergillosis. The breadth of late-stage and real-world data across antivirals, antibiotics and antifungals underscores Shionogi's focus on high medical-need infections and highlights the depth of its commercial and...
Yahoo · Oct 21, 2026
IDWeek 2026: Shionogi Presents U.S. Analysis of Real-World Data Showing Early Treatment Initiation with Fetroja®/Fetcroja® (cefiderocol) Improved Clinical Outcomes in Patients with Respiratory Infections
OSAKA, Japan, October 21, 2026--Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.; hereafter "Shionogi") will present new data at IDWeek 2026 that reinforce the role of Fetroja®/Fetcroja® (cefiderocol), an innovative siderophore cephalosporin, in serious Gram-negative infections.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
